We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · August 31, 2022

Risk of irAEs in Patients With Autoimmune Diseases Treated With ICIs for Stage III or IV Melanoma

Annals of the Rheumatic Diseases


Additional Info

Disclosure statements are available on the authors' profiles:

Annals of the Rheumatic Diseases
Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control study
Ann. Rheum. Dis 2022 Jul 04;[EPub Ahead of Print], L Plaçais, S Dalle, O Dereure, S Trabelsi, S Dalac, D Legoupil, H Montaudié, JP Arnault, J De Quatrebarbes, P Saiag, F Brunet-Possenti, T Lesimple, E Maubec, F Aubin, F Granel-Brocard, JJ Grob, PE Stoebner, C Allayous, B Oriano, C Dutriaux, L Mortier, C Lebbe

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading